Pharmaceuticals, Biotechnology and Life Sciences
Company to host conference call on Wednesday, December 11, 2024 at 7am ETCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) —…
January 13-16, 2025, San Francisco, CAIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics…
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study…
SHANGHAI, Dec. 08, 2024 (GLOBE NEWSWIRE) — Shanghai Zelixir Biotechnology Co., Ltd. (“Zelixir”) today announced the official operation of its…
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – –…
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4…
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response…
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of…
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including…